FOXP1 Syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:391372OMIM:613670Q87.0
Who is this for?
Show terms as
23Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

FOXP1 syndrome is a rare genetic condition caused by changes (mutations) in the FOXP1 gene. This gene plays an important role in brain development, and when it does not work properly, it can lead to a range of developmental and neurological challenges. The condition is also sometimes called FOXP1-related intellectual disability or mental retardation, autosomal dominant 32 (MRD32). Children with FOXP1 syndrome typically show delays in speech and language development, which is often one of the earliest and most noticeable features. Most individuals have mild to moderate intellectual disability, and many experience difficulties with motor skills such as walking and coordination. Behavioral features are common and can include autism spectrum traits, anxiety, and attention difficulties. Some children also have heart defects, vision problems, or distinctive facial features. There is currently no cure for FOXP1 syndrome. Treatment focuses on managing symptoms and supporting development through speech therapy, occupational therapy, physical therapy, and behavioral interventions. Early intervention services can make a meaningful difference in a child's progress. Some individuals may need additional support for heart problems or other medical issues. Research into this condition is ongoing, and the medical community continues to learn more about how best to support affected individuals and their families.

Also known as:

Key symptoms:

Delayed speech and language developmentIntellectual disability (usually mild to moderate)Delayed motor milestones like sitting and walkingAutism spectrum featuresAnxiety and mood difficultiesAttention and hyperactivity problemsLow muscle tone (feeling floppy)Heart defects (present in some individuals)Distinctive facial featuresVision problems such as strabismus (crossed eyes)Feeding difficulties in infancyCoordination and balance problemsKidney or urinary tract abnormalities (in some cases)Sleep difficulties

Clinical phenotype terms (50)— hover any for plain English
Expressive language delayHP:0002474Abnormality of refractionHP:0000539
Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Infantile

Begins in infancy, roughly 1 month to 2 years old

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for FOXP1 Syndrome.

View clinical trials →

No actively recruiting trials found for FOXP1 Syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the FOXP1 Syndrome community →

Specialists

23 foundView all specialists →
PP
Pauline Chaste, MD, PhD
Specialist
PI on 1 active trial
MM
Maryse Pagnier, MD
Specialist
PI on 1 active trial
AK
Alexander Kolevzon
NEW YORK, NY
Specialist
3 FOXP1 Syndrome publications
SK
Saskia Koene
Specialist
3 FOXP1 Syndrome publications
JW
Jing Wang
Specialist
2 FOXP1 Syndrome publications
HF
Henning Fröhlich
Specialist
2 FOXP1 Syndrome publications
GR
Gudrun A Rappold
Specialist
2 FOXP1 Syndrome publications
RL
Reymundo Lozano
NEW YORK, NY
Specialist
2 FOXP1 Syndrome publications
PS
Paige M Siper
NEW YORK, NY
Specialist
2 FOXP1 Syndrome publications
YF
Yitzchak Frank
BEAVERTON, OR
Specialist
2 FOXP1 Syndrome publications
JB
Joseph D Buxbaum
Specialist
2 FOXP1 Syndrome publications
TL
Tess Levy
LIVERPOOL, NY
Specialist
2 FOXP1 Syndrome publications
JW
Jannelien Wieland
Specialist
2 FOXP1 Syndrome publications
AM
Angela Morgan
Specialist
2 FOXP1 Syndrome publications
RB
Ruth Braden
Specialist
2 FOXP1 Syndrome publications
GS
Gijs W E Santen
Specialist
2 FOXP1 Syndrome publications
FT
Felipe Bodaleo Torres
CHICAGO, IL
Specialist
1 FOXP1 Syndrome publication
AM
Alexander Kolevzon, MD
NEW YORK, NY
Specialist
PI on 11 active trials1 FOXP1 Syndrome publication
PP
Paige Siper, Ph.D.
NEW YORK, NY
Specialist
PI on 2 active trials
RM
Reymundo Lozano, M.D.
NEW YORK, NY
Specialist
PI on 1 active trial
EP
Elodie Drapeau, Ph.D.
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to FOXP1 Syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open FOXP1 SyndromeForum →

No community posts yet. Be the first to share your experience with FOXP1 Syndrome.

Start the conversation →

Latest news about FOXP1 Syndrome

No recent news articles for FOXP1 Syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What specific genetic change was found in my child's FOXP1 gene, and what does it mean?,Should my child have a heart evaluation or other organ screening?,What therapies should we start right away, and how often should they occur?,Are there any clinical trials or research studies for FOXP1 syndrome that we could participate in?,What should we expect in terms of speech and language development over time?,How should we plan for my child's educational needs, and what school supports are available?,Is there a risk that future children could also have FOXP1 syndrome?

Common questions about FOXP1 Syndrome

What is FOXP1 Syndrome?

FOXP1 syndrome is a rare genetic condition caused by changes (mutations) in the FOXP1 gene. This gene plays an important role in brain development, and when it does not work properly, it can lead to a range of developmental and neurological challenges. The condition is also sometimes called FOXP1-related intellectual disability or mental retardation, autosomal dominant 32 (MRD32). Children with FOXP1 syndrome typically show delays in speech and language development, which is often one of the earliest and most noticeable features. Most individuals have mild to moderate intellectual disability,

How is FOXP1 Syndrome inherited?

FOXP1 Syndrome follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does FOXP1 Syndrome typically begin?

Typical onset of FOXP1 Syndrome is infantile. Age of onset can vary across affected individuals.

Which specialists treat FOXP1 Syndrome?

23 specialists and care centers treating FOXP1 Syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.